Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD™ 2026 Annual Meeting
TOKYO, March 10, 2026 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the company will present the latest findings on lecanemab (generic name, U.S. brand name: LEQEMBI ®), Eisai's anti-amyloid beta (Aβ) protofibril antibody for the treatment of Alzheimer's disease (AD), at the 20 th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD™ 2026) from March 17-21, in Copenhagen, Denmark, and online. The lecanemab data and additional research findings from Eisai's AD portfolio will be featured in six presentations, including three oral presentations. Eisai will host an industry-sponsored symposium.
Oral and Poster Presentations
Oral presentations will include the latest findings from a United States (U.S.) real-world long-term treatment persistence study, and efficacy and safety outcomes in apolipoprotein E ε4 (ApoEε4) homozygous carriers in a U.S. multicenter real-world study. In addition, four-year data from the Clarity AD Open-Label Extension trial in ApoEε4 non-carriers and heterozygotes, and a genome-wide association study on novel genetic variants associated with cognitive decline in AD will be presented as posters.
Eisai Symposium – Continue Life Their Way: Early Intervention in Alzheimer's Disease
Eisai is sponsoring a symposium featuring four leading global experts in the field of AD, on the topics of why early intervention matters, continuing early AD treatment and real-world outcomes. The symposium aims to enhance understanding of the value of early and continued anti-amyloid treatment in early AD by exploring how real-world evidence can support confident patient assessment in clinical practice, and how to recognize AD as a chronic condition that requires a multidisciplinary approach to care.
AD/PD™ 2026 Presentations Relating to Eisai's Key Compounds and Research
Oral Presentations
Asset / Topic, Session, Presentation Time (Central Europe Time: CET)
Presentation Title
Lecanemab
Real-World Outcomes and Mechanistic Insights in Anti-Amyloid Treatment
Friday, March 20, 16:50-17:05
Safety and Effectiveness of Lecanemab in Patients who are APOE4 Homozygous (E4/E4): Sub-Analysis from a US Multicenter, Retrospective Real-World Study (LEADER)
Lecanemab
Real-World Outcomes and Mechanistic Insights in Anti-Amyloid Treatment
Friday, March 20, 17:05-17:20
Long-Term Persistence and Patient Characteristics for Lecanemab in Real-World Use in the United States
Biomarkers and Imaging
Genomic Landscapes in AD, PD and Dementia
Wednesday, March 18, 16:15-16:30
Genome-wide Association Study in Mission AD Clinical Trials Identifies Novel Genetic Variants Associated with Cognitive Decline in Alzheimer's Disease
Poster Presentations
Asset / Project
Presentation Title
Lecanemab
Lecanemab for Early Alzheimer's Disease: 48-Month Results for APOE E4 Non-Carriers and Heterozygotes from the Clarity AD Open-Label Extension
Lecanemab
Reduction of Brain Aβ Protofibrils by Lecanemab Correlates with CSF pTau217 and Neuronal/Synaptic Biomarkers in APP NL-G-F/MAPT Double Knock-in Mice
Biomarkers and Imaging
Development of a Fully Automated Plasma pTau205 Immunoassay Demonstrating High Concordance with an Immunoprecipitation Mass Spectrometry Assay
(Collaboration with Sysmex)
Poster viewing time is from 7:30 on Tuesday, March 17 to 11:10 on Thursday, March 19 (CET).
Eisai-Sponsored Symposium: Industry Symposium 05
Wednesday, March 18, 11:10- 12:50 (CET)
Symposium Title: Continue Life Their Way: Early Intervention in Alzheimer's Disease
Identity and independence: Why early intervention matters
Extending the evidence over time: Continuing early AD treatment
Extending the evidence into clinical practice: Real-world outcomes
Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.
[Notes to editors]
References
1. Amin L, Harris DA. Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun. 2021;12: 3451. doi:10.1038/s41467-021-23507-z.
2. Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.
SOURCE Eisai Inc.